Literature DB >> 9353358

Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data.

T Iwatsubo1, H Suzuki, Y Sugiyama.   

Abstract

The bioavailability after oral administration of (S)-(-)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro [4,5] decane-L-tartarate monohydrate (YM796), which is being developed as an antidementia drug, at a dose of 1 mg/kg was very low (3.4%) in rats, but considerably higher (16.1%) in dogs. The oral clearances (CLoral, Dose/AUCoral) in rats and dogs were, respectively, 300 and 18 times more than that already reported in humans. We have previously reported successful attempts to predict the in vivo hepatic metabolic clearance of YM796 from in vitro data in humans. In our study, the in vitro metabolism of YM796 was determined using liver microsomes prepared from both rats and dogs and we also investigated if the species difference observed in vivo could be quantitatively reproduced in vitro. In rats, total metabolite formation could be described by single component kinetics with a Km of 13.4 microM and a Vmax of 520 nmol/min/g liver. However, in dogs, total metabolite formation could be described by three components, as also reported for humans. The Km and Vmax values for the high-affinity, low-capacity component (Km1 and Vmax1) in dogs and humans were, respectively, 8.1 and 1.7 microM, and 10.9 and 1.2 nmol/min/g liver. The overall intrinsic metabolic clearances estimated from the in vitro studies (CLint,in vitro) for rats and dogs were 38.8 and 2.6 ml/min/g liver, respectively, being approximately 40 and 3 times more than that previously reported for humans (0.94 ml/min/g liver). The overall intrinsic hepatic clearances (CLint,in vivo) calculated from in vivo CLoral were 30.4, 3.4 and 0.73 ml/min/g liver for rats, dogs and humans, respectively, indicating that the in vivo hepatic clearance of YM796 can be predicted from in vitro metabolism data in each species. Thus, the pronounced species difference in the metabolic clearance observed in vivo can be quantitatively predicted from in vitro metabolic data using liver microsomes, and was predominantly due to the large difference in the Vmax values.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353358

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

Review 1.  Prediction of hepatic metabolic clearance: comparison and assessment of prediction models.

Authors:  J Zuegge; G Schneider; P Coassolo; T Lavé
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.

Authors:  Kiyomi Ito; J Brian Houston
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

3.  Determination of the rate-limiting step in the hepatic elimination of YM796 by isolated rat hepatocytes.

Authors:  T Iwatsubo; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

4.  Dialing in on pharmacological features for a therapeutic antioxidant small molecule.

Authors:  Kayla N Green; Kristof Pota; Gyula Tircsó; Réka Anna Gogolák; Olivia Kinsinger; Collin Davda; Kimberly Blain; Samantha M Brewer; Paulina Gonzalez; Hannah M Johnston; Giridhar Akkaraju
Journal:  Dalton Trans       Date:  2019-07-25       Impact factor: 4.390

5.  Enhancement of the Antioxidant Activity and Neurotherapeutic Features through Pyridol Addition to Tetraazamacrocyclic Molecules.

Authors:  Hannah M Johnston; Kristof Pota; Madalyn M Barnett; Olivia Kinsinger; Paige Braden; Timothy M Schwartz; Emily Hoffer; Nishanth Sadagopan; Nam Nguyen; Yu Yu; Paulina Gonzalez; Gyula Tircsó; Hongli Wu; Giridhar Akkaraju; Michael J Chumley; Kayla N Green
Journal:  Inorg Chem       Date:  2019-11-27       Impact factor: 5.165

6.  Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model.

Authors:  Jia Li; Hai-Fang Guo; Can Liu; Zeyu Zhong; Li Liu; Xiao-Dong Liu
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

Review 7.  Phase 0/microdosing approaches: time for mainstream application in drug development?

Authors:  Tal Burt; Graeme Young; Wooin Lee; Hiroyuki Kusuhara; Oliver Langer; Malcolm Rowland; Yuichi Sugiyama
Journal:  Nat Rev Drug Discov       Date:  2020-09-08       Impact factor: 84.694

8.  Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches.

Authors:  Kiyomi Ito; J Brian Houston
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

9.  Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine.

Authors:  S Matsumoto; Y Yamazoe
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 10.  Factors affecting the relative importance of amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans.

Authors:  M Strolin Benedetti; K F Tipton; R Whomsley; E Baltes
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.